Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	45.14B +172.3%
Revenue (ttm)	7.42B +16.5%
Net Income	920.34M +0.8%
EPS	1.68 +0.0%
Shares Out	543.49M
PE Ratio	49.42
Forward PE	31.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,800
Average Volume	1,316,397
Open	82.40
Previous Close	83.05
Day's Range	81.30 - 84.35
52-Week Range	30.75 - 92.00
Beta	0.51
RSI	72.67
Earnings Date	Mar 20, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,762
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY